Zacks Investment Research upgraded shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from a hold rating to a buy rating in a research report sent to investors on Monday. The brokerage currently has $61.00 price target on the stock.

According to Zacks, “Fresenius has had a disappointing run on the bourse over the last six months. However, a solid full-year guidance instills our confidence on the stock. We believe this is in tune with the ‘Growth Strategy 2020’, under which it aims to boost revenues to $28 billion by 2020, corresponding to an average annual growth rate of around 10%. A wide range of dialysis products, initiatives to gain market traction, strengthened international foothold, strategic acquisitions and divestments act as major catalysts.On the flipside, lackluster performance by the renal pharmaceutical segment is likely to dent Latin-American revenues in the coming quarters. Having a strong international foothold, Fresenius faces the brunt of stringent regulations in almost every country in which it operates. Thus, it has to fulfill specific legal requirements that include tough antitrust laws. Regulatory hurdles and competition in the niche markets are major headwinds.”

A number of other brokerages also recently issued reports on FMS. Royal Bank of Canada reissued a hold rating and set a $44.00 price target on shares of Fresenius Medical Care AG & Co. in a research report on Wednesday, September 13th. UBS Group raised Fresenius Medical Care AG & Co. from a sell rating to a neutral rating in a research report on Thursday, January 4th. DZ Bank reissued a buy rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, December 18th. Nord/LB reissued a buy rating on shares of Fresenius Medical Care AG & Co. in a research report on Wednesday, December 27th. Finally, Morgan Stanley downgraded Fresenius Medical Care AG & Co. from an overweight rating to an equal weight rating in a research report on Monday, December 11th. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $55.67.

Fresenius Medical Care AG & Co. (NYSE:FMS) traded up $0.62 during trading on Monday, hitting $55.21. The stock had a trading volume of 165,417 shares, compared to its average volume of 148,151. Fresenius Medical Care AG & Co. has a 52 week low of $39.46 and a 52 week high of $55.30. The company has a quick ratio of 0.98, a current ratio of 1.22 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $33,940.00, a P/E ratio of 22.72, a price-to-earnings-growth ratio of 2.26 and a beta of 0.45.

A number of large investors have recently modified their holdings of FMS. Bank of New York Mellon Corp grew its position in Fresenius Medical Care AG & Co. by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 50,834 shares of the company’s stock worth $2,458,000 after buying an additional 1,584 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in Fresenius Medical Care AG & Co. during the second quarter worth approximately $179,000. Neuberger Berman Group LLC grew its position in Fresenius Medical Care AG & Co. by 6.8% during the second quarter. Neuberger Berman Group LLC now owns 53,081 shares of the company’s stock worth $2,565,000 after buying an additional 3,370 shares in the last quarter. HPM Partners LLC acquired a new stake in Fresenius Medical Care AG & Co. during the second quarter worth approximately $221,000. Finally, Ameriprise Financial Inc. grew its position in Fresenius Medical Care AG & Co. by 8.9% during the second quarter. Ameriprise Financial Inc. now owns 12,028 shares of the company’s stock worth $581,000 after buying an additional 978 shares in the last quarter. 3.03% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.watchlistnews.com/fresenius-medical-care-ag-co-fms-upgraded-by-zacks-investment-research-to-buy/1800469.html.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care AG & Co. (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.